TTN/ TP53 mutation might act as the predictor for chemotherapy response in lung adenocarcinoma and lung squamous carcinoma patients

Dan Xue; Hongguang Lin; Lan Lin; Qiongying Wei; Sheng Yang; Xiangqi Chen

doi:10.21037/tcr-20-2568

TTN/ TP53 mutation might act as the predictor for chemotherapy response in lung adenocarcinoma and lung squamous carcinoma patients

Transl Cancer Res. 2021 Mar;10(3):1284-1294. doi: 10.21037/tcr-20-2568.

Authors

Dan Xue^#¹, Hongguang Lin^#¹, Lan Lin¹, Qiongying Wei¹, Sheng Yang², Xiangqi Chen¹

Affiliations

¹ Department of Respiratory Medicine, Fujian Medical University Union Hospital, Fuzhou, China.
² Department of Oncology, Fujian Medical University Union Hospital, Fuzhou, China.

^# Contributed equally.

Abstract

Background: Chemotherapy is the preferred treatment in many types of cancer including lung cancer. However, most of patients resist chemotherapy resulting in disease progressive and recurrence. Titin (TTN) mutation is proved as a beneficial role in lung squamous carcinoma (LUSC), but the predictive role on chemotherapy resistance of lung cancer is still limited and discussable.

Methods: Clinical information and related somatic mutation profiles were obtained from The Cancer Genome Atlas (TCGA) database and analyzed by R-Studio using R-package. Overall survival (OS) curve and the association between gene mutation and clinical features were determined by GraphPad 6.0 software.

Results: Available data including 563 lung adenocarcinoma (LUAD) and 505 LUSC subjects were included in this study. Among all patients, 205 out of 563 LUAD and 326 out of 505 LUSC patients displayed TTN gene mutation. When comparing the clinical features in TTN-mutated patients to patients without TTN mutation who received chemotherapy, the tumors were always located in the upper lung in LUAD patients with TTN mutation and most of TTN-mutated subjects were at low pathological stage, which was not observed in LUSC patients. However, patients with TTN-mutation, particularly missense mutation, had a higher chemosensitivity and longer OS period than that patients without TTN mutation in both LUAD and LUSC. Of note, LUAD and LUSC patients possessed favorable OS and better chemotherapy response benefiting from TTN/tumor protein 53 (TP53) double mutation compared to TTN and TP53 mutation alone, respectively. Additionally, TTN/TP53 double mutation-initiated high rate of chemotherapy response were largely concentrated within LUAD and LUSC patients whose anatomic neoplasm subdivision were located in the upper lung.

Conclusions: Collectively, TTN/TP53 co-mutation is possibly served as an effective predictor for OS and chemotherapy response in lung cancer.

Keywords: Lung adenocarcinoma (LUAD); chemotherapy response; gene mutation; lung squamous carcinoma (LUSC); titin (TTN); tumor protein 53 (TP53).